Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline

J Infect Dis. 2012 Apr 1;205(7):1131-41. doi: 10.1093/infdis/jis027. Epub 2012 Feb 20.

Abstract

Background: Natural killer (NK) cells likely contribute to outcome of acute hepatitis C virus (HCV) infection and interferon (IFN)-induced control of chronic HCV infection. We previously observed IFN-αR and NKp30 expression associated with IFN-α-dependent NK cell activity.

Methods: Here, we examined CD16(+)56(-), CD16(+)56(+), and CD16(-)56(+) NK cell subset IFN-αR and NKp30 expression in relation to magnitude of HCV genotype 1 decrease during pegylated IFN-α plus ribavirin therapy.

Results: We observed greater baseline IFN-αR and NKp30 expression on CD16(+)56(+) and CD16(-)56(+) NK subsets in HCV-infected patients than in healthy control subjects. Baseline CD16(+)56(-) NK IFN-αR expression was associated with IFN-α-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-α plus ribavirin therapy. Baseline CD16(+)56(-) NK IFN-αR expression was associated with race and interleukin 28B genotype, negatively associated with aspartate aminotransferase-to platelet ratio index, and positively associated with increase in NKp30 expression after in vivo IFN-α exposure. Finally, in vitro IFN-α2a-activated NK cytolysis of HCV-infected target cells was in part dependent on NKp30, and CD16(+)56(-) NK cell IFN-αR expression correlated with cytolytic activity.

Conclusions: IFN-αR expression on CD16(+)56(-) NK cells during chronic HCV infection may in part be genetically determined, and level of expression regulates IFN-α signaling, which in turn may contribute to control of HCV infection.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / administration & dosage
  • CD56 Antigen / analysis
  • Female
  • GPI-Linked Proteins / analysis
  • Gene Expression Regulation*
  • Hepacivirus / immunology*
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / immunology*
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferon-alpha / administration & dosage
  • Killer Cells, Natural / chemistry
  • Killer Cells, Natural / immunology*
  • Lymphocyte Subsets / chemistry
  • Lymphocyte Subsets / immunology
  • Male
  • Middle Aged
  • Natural Cytotoxicity Triggering Receptor 3 / biosynthesis
  • Natural Cytotoxicity Triggering Receptor 3 / immunology
  • Receptor, Interferon alpha-beta / biosynthesis*
  • Receptor, Interferon alpha-beta / immunology*
  • Receptors, IgG / analysis
  • Signal Transduction*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • CD56 Antigen
  • FCGR3B protein, human
  • GPI-Linked Proteins
  • Interferon-alpha
  • NCAM1 protein, human
  • NCR3 protein, human
  • Natural Cytotoxicity Triggering Receptor 3
  • Receptors, IgG
  • Receptor, Interferon alpha-beta